The Latest Cardiac and Vascular News
Press release Malmö, Sweden, February 17, 2022 Correction of press release: Acarix AB (publ) publishes Year-End Report 2021 The press release published today at 08.00 CET did not include the quarterly report. The quarterly report is included in the press release below, which otherwise correspond to the previously published press release. For more information contact: Christian […]
These authorizations enable the simultaneous launch of recruitment for these international studies, which should be completed in the first half of 2023. The INSIGHT and INSIGHT 2 randomized, placebo-controlled studies are designed to include a total of 800 volunteers with mild to moderate elevated blood pressure, with 400 volunteers in […]
Findings from Cleerly’s groundbreaking CLARIFY 2 study echo the recent American College of Cardiology guidelines on the use of CCTA for non-invasive heart disease evaluation. The study, the second of six studies comparing Cleerly analysis against current gold standards to plaque and coronary artery imaging, demonstrates Cleerly’s effectiveness in the identification and exclusion of […]
The new service will allow for frequent follow-ups, immediate medication or treatment adjustment, and more. New York, NY – February 17, 2022 – As the leading telehealth provider making quality healthcare accessible to all Americans, Antidote Health has announced a new core offering to their suite of services that will […]
PLANO, Texas, Feb. 16, 2022 /PRNewswire/ — MediLynx Cardiac Monitoring, LLC (dba MediLynx Arrhythmia Diagnostics™), a national remote monitoring provider and technology leader in deep learning artificial intelligence, has earned The Joint Commission’s Gold Seal of Approval® for Ambulatory Health Care Accreditation by demonstrating continuous compliance with its performance standards. The Gold Seal […]
MONTREAL and CHARLOTTE, N.C., Feb. 16, 2022 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of David Bharucha, M.D., Ph.D., as Chief Medical Officer, effective February 15, 2022. Dr. Bharucha is a cardiac electrophysiologist who brings to Milestone over thirty years of […]
SOUTH SAN FRANCISCO, Calif. and OAKLAND, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) and the American Heart Association (AHA) Bay Area today announced a three-year collaboration to accelerate education and awareness of heart disease. Within the collaboration, Cytokinetics will provide funding and support for several initiatives […]
Fourth Quarter 2021 Revenue of $3.7 million, a 75% Increase Over Prior Year MINNEAPOLIS, Feb. 15, 2022 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results […]
– Phase 1/2 clinical trial expected to initiate in mid-2022 – – LX2006 is the first clinical-stage program from LEXEO’s cardiovascular pipeline and the third clinical-stage gene therapy candidate across its pipeline – NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) — LEXEO Therapeutics (LEXEO), a clinical-stage gene therapy company advancing a diverse […]
Cardiovascular disease (CVD), a leading cause of death and disability worldwide, involves structural and functional changes in the heart Local sterile inflammation by the innate immune system results in a signalling cascade, particularly activation of NLRP3 NLRP3 activation, along with processing and release of downstream associated pro-inflammatory cytokines, IL-1β and […]
